Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Febrile Neutropenia 3Prostatic Neoplasms 2Neutropenia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pancreatic Cyst 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Infections 1Hematologic Neoplasms 1Early Stage Breast Cancer 1Cysts 1Cystectomy 1Breast Neoplasms 1

Interventions

Gemcitabine 3Ethanol 3fish oil triglycerides 2S 1 (combination) 2Metronidazole 2Long-Term Synaptic Depression 2Dexamethasone 2pembrolizumab 1pasireotide 1nimotuzumab 1ferumoxtran-10 1alanylglutamine 1Tobacco Use Cessation Devices 1TachoSil 1Sunitinib 1Psychiatric Rehabilitation 1Pregabalin 1Polymerase Chain Reaction 1Polygeline 1Parenteral Nutrition 1Pancrelipase 1Oxaliplatin 1Nutritional Status 1Needles 1Mirtazapine 1Midazolam 1Meperidine 1Immunonutrition Diet 1Hydrocortisone 1Glucocorticoids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Pancreatic Neoplasms × Ciprofloxacin × Clear all
NCT03891979 2020-06-26

Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma

NYU Langone Health

Phase 4 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡